BR9508295A - Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina - Google Patents
Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopaminaInfo
- Publication number
- BR9508295A BR9508295A BR9508295A BR9508295A BR9508295A BR 9508295 A BR9508295 A BR 9508295A BR 9508295 A BR9508295 A BR 9508295A BR 9508295 A BR9508295 A BR 9508295A BR 9508295 A BR9508295 A BR 9508295A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- dopamine
- respond
- preparing
- processes
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 thiadiazole compound Chemical class 0.000 title 1
- 150000003557 thiazoles Chemical class 0.000 title 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000004867 thiadiazoles Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Lubricants (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4425145A DE4425145A1 (de) | 1994-07-15 | 1994-07-15 | Verwendung von Thiazol- und Thiadiazolverbindungen |
| PCT/EP1995/002783 WO1996002249A1 (de) | 1994-07-15 | 1995-07-14 | Verwendung von thiazol- und thiadiazolverbindungen als d3 dopaminrezeptorligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9508295A true BR9508295A (pt) | 1998-01-13 |
Family
ID=6523324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9508295A BR9508295A (pt) | 1994-07-15 | 1995-07-14 | Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5958923A (pt) |
| EP (1) | EP0768879B1 (pt) |
| JP (1) | JPH10502915A (pt) |
| KR (1) | KR100443216B1 (pt) |
| CN (1) | CN1152872A (pt) |
| AT (1) | ATE234616T1 (pt) |
| AU (1) | AU712422B2 (pt) |
| BR (1) | BR9508295A (pt) |
| CA (1) | CA2195240A1 (pt) |
| CZ (1) | CZ292909B6 (pt) |
| DE (2) | DE4425145A1 (pt) |
| ES (1) | ES2194918T3 (pt) |
| FI (1) | FI970149A (pt) |
| HU (1) | HUT77554A (pt) |
| IL (1) | IL114600A (pt) |
| MX (1) | MX9700429A (pt) |
| NO (1) | NO312154B1 (pt) |
| SI (1) | SI9520081B (pt) |
| TW (1) | TW414793B (pt) |
| WO (1) | WO1996002249A1 (pt) |
| ZA (1) | ZA955869B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| MA26696A1 (fr) | 1998-10-08 | 2004-12-20 | Smithkline Beecham Plc | Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU2001250404A1 (en) * | 2000-03-27 | 2001-10-08 | Basf Aktiengesellschaft | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| AU2003205747A1 (en) * | 2002-03-06 | 2003-09-16 | Merck Patent Gmbh | Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands |
| US7605259B2 (en) | 2002-09-14 | 2009-10-20 | University Of North Texas Health Science Center At Fort Worth | Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
| US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
| DE10358004A1 (de) | 2003-12-11 | 2005-07-14 | Abbott Gmbh & Co. Kg | Ketolactam-Verbindungen und ihre Verwendung |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| WO2005058328A1 (en) | 2003-12-18 | 2005-06-30 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| DE102004027358A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| JP4904267B2 (ja) * | 2004-08-09 | 2012-03-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物 |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| CN101663292A (zh) * | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物 |
| CA2682671C (en) * | 2007-04-23 | 2015-11-17 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| LT2307374T (lt) * | 2008-07-31 | 2017-04-25 | Janssen Pharmaceutica Nv | Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai |
| WO2018021447A1 (ja) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物 |
| WO2019146739A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する縮環化合物 |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| CN118647615A (zh) | 2022-01-29 | 2024-09-13 | 苏文生命科学有限公司 | 用于治疗精神障碍的苯并异噻唑和苯并异噁唑化合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053085A (pt) * | 1964-03-26 | |||
| DE1695410A1 (de) * | 1967-04-20 | 1971-04-08 | Merck Patent Gmbh | Verfahren zur Herstellung von 1-(Thiazolyl-5-alkyl)-4-(pyridyl-2)-piperazinen |
| US3522846A (en) * | 1968-10-04 | 1970-08-04 | Robert V New | Method and apparatus for production amplification by spontaneous emission of radiation |
| US3717651A (en) * | 1970-04-20 | 1973-02-20 | Shell Oil Co | Thiazoles |
| US4074049A (en) * | 1976-11-19 | 1978-02-14 | The Dow Chemical Company | Antithrombotic 1,3,4-thiadiazole |
| NZ223654A (en) * | 1987-03-09 | 1990-03-27 | Janssen Pharmaceutica Nv | 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions |
| US4943580A (en) * | 1987-03-09 | 1990-07-24 | Janssen Pharmaceutica N.V. | Anti-histaminic benzimidazole, imidazopyridine and purine derivatives |
| US4935424A (en) * | 1988-05-27 | 1990-06-19 | Warner-Lambert Company | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents |
| FR2636628B1 (fr) * | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
| DE3923675A1 (de) * | 1989-07-18 | 1991-01-24 | Basf Ag | Amonoalkylsubstituierte 2-aminothiazole und diese enthaltende therapeutische mittel |
| US5273977A (en) * | 1990-11-05 | 1993-12-28 | Warner-Lambert Company | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents |
| DE4119755A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 2-amino-1,3,4-thiadiazole, ihre herstellung und verwendung |
| DE4119756A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung |
| DE4119757A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung |
| DE4119758A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 2-amino-5-mercaptothiadiazole, ihre herstellung und verwendung |
| ZA9610046B (en) * | 1995-12-01 | 1997-07-10 | Ciba Geigy | Process for preparing 2-chlorothiazole compounds |
-
1994
- 1994-07-15 DE DE4425145A patent/DE4425145A1/de not_active Withdrawn
-
1995
- 1995-07-14 DE DE59510596T patent/DE59510596D1/de not_active Expired - Lifetime
- 1995-07-14 SI SI9520081A patent/SI9520081B/sl not_active IP Right Cessation
- 1995-07-14 CN CN95194140A patent/CN1152872A/zh active Pending
- 1995-07-14 AT AT95926897T patent/ATE234616T1/de not_active IP Right Cessation
- 1995-07-14 BR BR9508295A patent/BR9508295A/pt not_active Application Discontinuation
- 1995-07-14 US US08/765,915 patent/US5958923A/en not_active Expired - Lifetime
- 1995-07-14 IL IL11460095A patent/IL114600A/xx not_active IP Right Cessation
- 1995-07-14 CZ CZ199794A patent/CZ292909B6/cs not_active IP Right Cessation
- 1995-07-14 AU AU31115/95A patent/AU712422B2/en not_active Ceased
- 1995-07-14 ZA ZA955869A patent/ZA955869B/xx unknown
- 1995-07-14 EP EP95926897A patent/EP0768879B1/de not_active Expired - Lifetime
- 1995-07-14 HU HU9700115A patent/HUT77554A/hu unknown
- 1995-07-14 JP JP8504702A patent/JPH10502915A/ja not_active Ceased
- 1995-07-14 MX MX9700429A patent/MX9700429A/es not_active IP Right Cessation
- 1995-07-14 KR KR1019970700268A patent/KR100443216B1/ko not_active IP Right Cessation
- 1995-07-14 CA CA002195240A patent/CA2195240A1/en not_active Abandoned
- 1995-07-14 WO PCT/EP1995/002783 patent/WO1996002249A1/de active IP Right Grant
- 1995-07-14 ES ES95926897T patent/ES2194918T3/es not_active Expired - Lifetime
- 1995-08-08 TW TW084108222A patent/TW414793B/zh not_active IP Right Cessation
-
1997
- 1997-01-14 FI FI970149A patent/FI970149A/fi not_active IP Right Cessation
- 1997-01-14 NO NO19970164A patent/NO312154B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SI9520081A (en) | 1997-08-31 |
| US5958923A (en) | 1999-09-28 |
| ES2194918T3 (es) | 2003-12-01 |
| ATE234616T1 (de) | 2003-04-15 |
| DE4425145A1 (de) | 1996-01-18 |
| KR100443216B1 (ko) | 2004-11-20 |
| TW414793B (en) | 2000-12-11 |
| JPH10502915A (ja) | 1998-03-17 |
| EP0768879B1 (de) | 2003-03-19 |
| KR970704438A (ko) | 1997-09-06 |
| CZ9497A3 (en) | 1997-09-17 |
| CZ292909B6 (cs) | 2004-01-14 |
| EP0768879A1 (de) | 1997-04-23 |
| NO312154B1 (no) | 2002-04-02 |
| MX9700429A (es) | 1998-05-31 |
| IL114600A (en) | 1999-11-30 |
| AU3111595A (en) | 1996-02-16 |
| NO970164L (no) | 1997-03-14 |
| SI9520081B (sl) | 2003-12-31 |
| FI970149A0 (fi) | 1997-01-14 |
| HUT77554A (hu) | 1998-05-28 |
| NO970164D0 (no) | 1997-01-14 |
| DE59510596D1 (de) | 2003-04-24 |
| CA2195240A1 (en) | 1996-02-01 |
| CN1152872A (zh) | 1997-06-25 |
| IL114600A0 (en) | 1995-11-27 |
| HU9700115D0 (en) | 1997-02-28 |
| AU712422B2 (en) | 1999-11-04 |
| WO1996002249A1 (de) | 1996-02-01 |
| ZA955869B (en) | 1997-01-14 |
| FI970149A (fi) | 1997-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9508295A (pt) | Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina | |
| HU9700111D0 (en) | Use of heterocyclic compounds as dopamines-d3 ligands | |
| FI970147A0 (fi) | Triatsoliyhdisteitä ja niiden käyttö dopamiini-D3-ligandeina | |
| IL114599A0 (en) | Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them | |
| ATE216891T1 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
| HUT73231A (en) | Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B23G | Processing applications according to articles 230 and 231 of law 9.279/96: application refusal | ||
| B25A | Requested transfer of rights approved |
Free format text: ABBOTT GMBH & CO. KG. (DE) |